iBio, Inc.
iBio, Inc. (Nasdaq: IBIO) is a clinical-stage biotechnology company developing AI-designed antibody therapeutics for obesity and related cardiometabolic and cardiopulmonary diseases. Its pipeline includes IBIO-600, a myostatin antibody in Phase 1 clinical development; IBIO-610, an Activin E antibody in preclinical… From the company’s description.
In fiscal 2026, iBio, Inc. reported revenue of $0.10M, down 75.0% from fiscal 2025, and a net loss of $33.04M. Operations used $23.22M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What iBio, Inc. does
In the company’s own words
iBio, Inc. (Nasdaq: IBIO) is a clinical-stage biotechnology company developing AI-designed antibody therapeutics for obesity and related cardiometabolic and cardiopulmonary diseases. Its pipeline includes IBIO-600, a myostatin antibody in Phase 1 clinical development; IBIO-610, an Activin E antibody in preclinical development; and IBIO-800, a bispecific antibody targeting myostatin and Activin A for potential use in obesity and cardiopulmonary conditions. The company also develops amylin receptor agonist antibodies and has preclinical immuno-oncology programs, including TROP-2 × CD3, EGFRvIII and CCR8 antibodies. Its AI Drug Discovery Platform combines Epitope Steering for antibody discovery, StableHu for optimization, mammalian display screening and EngageTx for therapeutic engineering. iBio conducts research and development at its San Diego laboratory and collaborates with AstralBio on antibody discovery and development; it also licenses its platform and evaluates partnerships in areas beyond its core therapeutic focus. In fiscal 2026, iBio reported revenue of $0. Its website is http://www.ibioinc.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- June
- CIK
- 1420720
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns iBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · iBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do iBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of iBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in iBio, Inc.'s last four quarterly filings that the numbers alone won't show?”